3009, 2024
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA June 17 - Capivasertib – BC PIK3CA/AKT1/PTEN. The European Commission (EC) has [...]
1107, 2024
Shooting Cancer Highlights – Periodic Focus on regulatory status of new targeted therapies in oncology
EMA May 28 - Selpercatinib – Solid Tumours RET. [...]
1405, 2024
Shooting Cancer Highlights – Periodic Focus on regulatory status of new targeted therapies in oncology
EMA April 23 - Tislelizumab – NSCLC EGFR/ALK. The [...]
1303, 2024
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA November 15 - Dabrafenib – LGG/HGG BRAF. The [...]
2112, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology –November 2023
EMA October 18 - Trastuzumab deruxtecan – NSCLC HER2. [...]
611, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – September and October 2023
EMA September 6 - Pembrolizumab – GC/GEJC HER2/PD-L1. The [...]
2806, 2023
Shooting Cancer Highlights – Monthly focus on regulatory status of new targeted therapies in oncology – April and May 2023
April 4. Tremelimumab + Durvalumab – NSCLC EGFR/ALK. The [...]
203, 2023
Shooting Cancer- Highlights Monthly focus on regulatory status of new targeted therapies in oncology – January 2023
FDA January 19. Tucatinib + trastuzumab – CRC RAS/HER2. [...]